New inhaler hope for COPD patients in early trial
NCT ID NCT07640451
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study tests a new inhaled drug called HRS-9821 in people with moderate to severe COPD. About 90 participants will receive either the drug or a placebo for 28 days. The main goal is to see if the drug improves lung function, measured by how much air they can exhale in one second.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HRS-9821 inhalation suspension
What this could lead to
If successful, this could lead to a new inhaled treatment option for people with moderate to severe COPD, potentially improving their lung function and daily breathing.
What could go wrong
This is an early Phase 2 trial with only 90 participants, so results may not apply to everyone. The drug may not work better than placebo, and side effects are still being studied.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC OBSTRUCTIVE PULMONARY DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai Tongji Hospital
Shanghai, Shanghai Municipality, 200065, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact